BIONTO Ltd closed its funding round by signing an investment agreement of EUR 4 million with Korpi Capital and welcomed the new partner to the Board.
“The signed investment agreement enables our operational business and ensures the company’s growth, and we would like to sincerely thank Korpi Capital for the trust. Korpi Capital will be a valuable and reliable partner for us.“
Chief Scientist, Founder
I have built my scientific and technological expertise in the development of microbial strains, platforms, and industrial enzymes. My focus has been and continues to be on enabling the efficient, industrially feasible cell-based production of high-quality biological products.
Working as an expert in a highly competent R&D team is rewarding. I believe that success lies in a consistent and structured way of working that supports innovation and growth.
“I’m a team player and enjoy brainstorming together with colleagues. I value trust, authenticity, and openness – supporting individual and organisational growth.“
CEO, Founder
I have had the privilege of leading highly successful teams in the industrial enzyme business that have developed competitive products for the mass market for 15 years. I have ensured business competitiveness by building an IP portfolio, and most importantly, by providing day-to-day stakeholder/customer support.
It should come as no surprise that technological development also inspires me. I have designed and led strategies, roadmaps and projects in terms of cell-based production platforms, Bio-IT and R&D digitalization.
“I want to be a value-adding leader that foster a culture of trust, collaboration and learning. I believe it enables our customers to reach their full potential and succeed beyond expectations.“
CTO, Founder
My technological foundation is built on the design of industrial crystallization processes for concentrated and purified products ranging from therapeutic proteins to enzymes. I am delighted to have been able to provide R&D services that are trusted by many, including some of the world’s largest pharmaceutical companies.
That decade was just an appetizer. It was followed by a deeper dive into industrial upscaling, particularly enzyme processing and formulation technologies, leading up to hundreds of commercial bulk enzyme products.
”Set a goal. My passion is to design the most high-quality, streamlined and cost-effective process to achieve the given goal.”
